Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887083 | 0.80 | SMN1; SMN2 (0.47) | KCNA5ALDH1A1L3MBTL1NAPRTGAA | |
| SCHEMBL5218484 | 0.78 | CYP11B1 (0.40) | NAPRTGAA | |
| SCHEMBL5214892 | 0.77 | GAA (0.40) | KCNA5ALDH1A1L3MBTL1NAPRTKCND3 | |
| SCHEMBL2901635 | 0.70 | CYP2C19 (0.45) | KCNA5ALDH1A1L3MBTL1NAPRTCYP3A4 | |
| SCHEMBL23490092 | 0.70 | NAPRT (0.42) | L3MBTL1NAPRTCYP3A4GAA | |
| SCHEMBL3647568 | 0.70 | NAPRT (0.42) | L3MBTL1NAPRTCYP3A4GAA | |
| SCHEMBL5214224 | 0.68 | TSHR (0.50) | ALDH1A1L3MBTL1NAPRTMAPT | |
| SCHEMBL24805800 | 0.67 | NAPRT (0.40) | KCNA5L3MBTL1NAPRTKCND3CYP3A4 | |
| SCHEMBL25356422 | 0.67 | LOXL2 (0.50) | L3MBTL1CYP3A4LOXL2MAPT | |
| SCHEMBL7455518 | 0.67 | NAPRT (0.40) | ALDH1A1L3MBTL1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| EP-1751119-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | VIP, CCKBR, HRH2 | KCNA5 4023/4885ALDH1A1 836/4885L3MBTL1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.